PCAC July 2026 Live Tracker: Vote-by-Vote on All 7 Peptides

This is the single most important regulatory event in the peptide space in 2026. On July 23–24, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will evaluate seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List. A favorable recommendation would open a legal compounding pathway for tens of thousands of patients currently buying research-grade peptides through gray-market channels.

Here’s the schedule, broken down by day, with our pre-meeting analysis of each peptide’s chances and what the outcome means for access.

Day 1 — July 23, 2026

Day 2 — July 24, 2026

What the PCAC Actually Decides

Let’s be precise about what’s happening here, because the internet is full of people getting this wrong.

The PCAC is an advisory committee. It makes recommendations to the FDA — it does not make binding decisions. For each peptide, the committee evaluates four factors from the nominator’s submission:

1. Physical and chemical characterization — Can the substance be reliably identified and tested for purity?
2. Safety — What does the available evidence say about adverse effects at the nominated dose range?
3. Effectiveness — Is there reasonable clinical or preclinical evidence supporting the nominated use?
4. Historical use in compounding — Has this substance been compounded before, and if so, what does that track record look like?

After evaluating each factor, the committee votes on whether to recommend the substance for the 503A Bulks List. If the vote is favorable, the FDA then initiates a formal rulemaking process to actually add it. That rulemaking takes months — realistically, any peptide that gets a “yes” vote in July won’t be available through compounding pharmacies until late 2026 at the earliest, more likely Q1 2027.

Why the Realistic Outcome Is Mixed

The peptide community is mostly treating this meeting as a foregone conclusion — that all seven will sail through because HHS Secretary Kennedy signaled support. That’s not how this works.

The PCAC evaluates each substance individually, and the evidence base varies dramatically across these seven nominations. BPC-157 has decades of published research (albeit mostly preclinical) and a nominated use — ulcerative colitis — supported by Sikiric’s extensive angiogenesis and nitric-oxide pathway work. KPV has a clean safety profile and solid wound-healing data. Those two are the strongest candidates.

At the other end, Epitalon’s nomination for “healthy aging” is extraordinarily broad, the human evidence is thin, and the Khavinson lab’s telomere data has methodological questions. MOTS-C is being evaluated for two indications simultaneously — obesity and osteoporosis — which is ambitious given that the human metabolic data is still early-stage. DSIP’s nomination includes opioid withdrawal, which puts it in a high-scrutiny regulatory lane.

Our realistic prediction: two to three favorable recommendations, two to three deferrals, and one or two outright rejections. Rulemaking on the favorable substances will stretch into 2027. The five additional peptides scheduled for a later PCAC meeting (before end of February 2027) will follow a similar mixed trajectory.

What Happens If a Peptide Gets a “Yes”

A favorable PCAC recommendation does not make the peptide immediately available. Here’s the actual timeline:

1. PCAC votes yes (July 23–24, 2026)
2. FDA reviews recommendation and drafts proposed rulemaking (weeks to months)
3. Proposed rule published in the Federal Register with public comment period (typically 60 days)
4. Final rule published after reviewing comments
5. Compounding pharmacies can then legally prepare the substance under 503A with individual prescriptions

The fastest realistic path from a July “yes” vote to pharmacy availability is 4–6 months. That puts us in late 2026 or early 2027 for the first peptides to become legally compoundable.

What Happens If a Peptide Gets a “No”

A negative recommendation doesn’t permanently kill the substance. The nominator can resubmit with additional data for a future PCAC meeting. But it does push the timeline out by at least a year, and in the interim, the substance remains in a regulatory gray zone where 503A compounders technically shouldn’t be using it.

The practical effect of a “no” vote is that patients continue being pushed toward unregulated research-grade vendors with no quality controls or physician oversight — exactly the outcome the FDA claims to be trying to prevent.

How to Follow the Meeting Live

The PCAC meeting at FDA White Oak Campus in Silver Spring, Maryland will have a virtual attendance option. Open public hearing sessions are scheduled throughout both days. FDA intends to publish background materials at least two business days before the meeting — look for them on the FDA advisory committee calendar page.

The federal docket number is FDA-2025-N-6895. Public comments submitted before the meeting may influence the committee’s deliberations. We’ll update this page in real time as each vote comes in.

Where to Source Research Peptides Now

While the regulatory process plays out, these vetted research peptide vendors provide third-party tested compounds with certificates of analysis. All products are sold for research purposes only.

Frequently Asked Questions

Related Articles